India and clinical trials : no denoument in sight

There are murmurs among clinical research industry executives that India's health ministry will reexamine some of the clauses in the rules on compensation in case of clinical trial injury that it had notified in the Gazette of India in February and that had caused grave concern among trial sponsors. This follows discussions between the industry …

Advertisement

Guest column on India & drug patents: Can the US force policy change?

The pharma giant Pfizer wants the US government to act more aggressively to defend the interests of the research-based pharmaceutical sector in India. Will it succeed? The path from lobbying in Washington, D.C, to a change of policy in India is a long and uncertain one involving multiple steps. First, Pfizer needs to convince Congress …

India’s report on patented drug pricing : on unsure ground

Last week saw the release of a draft of the Report of the Committee on Price Negotiation for Patented Drugs. Yet, far from inspiring confidence in India's ability to get a good deal for its patients, it strikes a note of  pessimism that belies the leverage that a strong generics industry and a vast and …